DR. AYSE SULE TINAZ M.D., PH.D.
Prescription History 1285809749
Psychiatry & Neurology - Neurology in New Haven, CT


Quality Rating: 73.56 out of 100 score

NPI Status: Active since April 25, 2008

Contact Information

800 HOWARD AVE # LL
NEW HAVEN, CT
ZIP 06519
Phone: (203) 785-4085

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. AYSE SULE TINAZ M.D., PH.D., an active Neurology specialist practicing in New Haven, CT. Our medical registry currently tracks 17 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 724 documented patient claims. Among these therapy options, the most frequently utilized medication is Carbidopa-Levodopa, which accounts for 239 claims alone.


Amantadine

Generic Formulation: Amantadine HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 45.0
Days Supply 1,350
CT State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills44.0
Peer Average Days Supply1,277
Conservative Utilization

This provider writes prescriptions for this formulation 48.3% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,478.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$98.55

State Avg Cost Per Claim

$76.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.

Therapeutic Applications

Amantadine is used to treat Parkinson's disease, as well as side effects caused by drugs (such as drug-induced extrapyramidal symptoms), chemicals, and other medical conditions. In these cases, this medication may help to improve your range of motion and ability to exercise. For the treatment of these conditions, amantadine is believed to work by restoring the balance of natural chemicals (neurotransmitters) in the brain. Amantadine is used to prevent or treat a certain type of flu (influenza A). If you have been infected with the flu, this medication may help make your symptoms less severe and shorten the time it will take you to get better. Taking amantadine if you have been or will be exposed to the flu may help to prevent you from getting the flu. This medication is an antiviral that is believed to work by stopping growth of the flu virus. This medication is not a vaccine. To increase the chance that you will not get the flu, it is important to get a flu shot once a year at the beginning of every flu season, if possible. Based on the recommendation from the Centers for Disease Control (CDC) in the US, amantadine should not be used to treat or prevent influenza A because the current influenza A virus in the United States and Canada is resistant to this medication. For more details, talk to your doctor or pharmacist.

Baclofen

Generic Formulation: BaclofenSpecialty: Neurology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills48.0
Peer Average Days Supply1,322
Conservative Utilization

This provider writes prescriptions for this formulation 36.1% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $155.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.75

State Avg Cost Per Claim

$39.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.

Therapeutic Applications

Baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Neurology
Provider Metrics Summary
Total Claims 239
30-Day Fills 510.7
Days Supply 15,253
CT State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills122.6
Peer Average Days Supply3,556
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 246.4% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,549.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.88

State Avg Cost Per Claim

$51.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Carbidopa-Levodopa Er

Generic Formulation: Carbidopa/LevodopaSpecialty: Neurology
Provider Metrics Summary
Total Claims 47
30-Day Fills 101.0
Days Supply 3,030
CT State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills82.9
Peer Average Days Supply2,431
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,877.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.96

State Avg Cost Per Claim

$68.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Carbidopa-Levodopa-Entacapone

Generic Formulation: Carbidopa/Levodopa/EntacaponeSpecialty: Neurology
Provider Metrics Summary
Total Claims 20
30-Day Fills 51.3
Days Supply 1,538
CT State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills42.4
Peer Average Days Supply1,144
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,668.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$333.45

State Avg Cost Per Claim

$378.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa and entacapone prevent the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Clonazepam

Generic Formulation: ClonazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 99
30-Day Fills 119.0
Days Supply 3,523
CT State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills59.8
Peer Average Days Supply1,693
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 90.4% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,267.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.80

State Avg Cost Per Claim

$10.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 20.0
Days Supply 600
CT State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills71.1
Peer Average Days Supply2,021
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.6% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $148.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.31

State Avg Cost Per Claim

$27.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Nuplazid

Generic Formulation: Pimavanserin TartrateSpecialty: Neurology
Provider Metrics Summary
Total Claims 28
30-Day Fills 36.0
Days Supply 1,080
CT State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.2
Peer Average Days Supply671
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $166,703.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,953.71

State Avg Cost Per Claim

$3,813.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions). Pimavanserin belongs to a class of drugs known as atypical antipsychotics, though it works differently from most other drugs in this class.

Primidone

Generic Formulation: PrimidoneSpecialty: Neurology
Provider Metrics Summary
Total Claims 31
30-Day Fills 45.0
Days Supply 1,350
CT State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills55.5
Peer Average Days Supply1,628
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,221.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.39

State Avg Cost Per Claim

$36.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Primidone belongs to a class of drugs known as barbiturate anticonvulsants. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

Propranolol Hcl

Generic Formulation: Propranolol HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 36
30-Day Fills 58.0
Days Supply 1,710
CT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills38.5
Peer Average Days Supply1,117
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.5% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $845.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.50

State Avg Cost Per Claim

$28.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This formulation of propranolol is used for infants and children to treat a certain benign tumor (proliferating infantile hemangioma). It helps to shrink the tumor. Propranolol belongs to a class of drugs known as beta blockers.

Quetiapine Fumarate

Generic Formulation: Quetiapine FumarateSpecialty: Neurology
Provider Metrics Summary
Total Claims 19
30-Day Fills 37.0
Days Supply 1,110
CT State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills75.5
Peer Average Days Supply2,132
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $316.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.65

State Avg Cost Per Claim

$35.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

Therapeutic Applications

This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. It may also improve your mood, sleep, appetite, and energy level. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur.

Rasagiline Mesylate

Generic Formulation: Rasagiline MesylateSpecialty: Neurology
Provider Metrics Summary
Total Claims 22
30-Day Fills 42.0
Days Supply 1,260
CT State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills69.6
Peer Average Days Supply2,035
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,077.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$230.79

State Avg Cost Per Claim

$403.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of off time (periods of slow movement or stiffness). Rasagiline belongs to a class of drugs known as MAO inhibitors. It works by increasing the levels of certain natural substances in the brain (such as dopamine, norepinephrine, serotonin). Parkinson's disease is thought to be caused by too little dopamine in the brain.

Rivastigmine

Generic Formulation: Rivastigmine TartrateSpecialty: Neurology
Provider Metrics Summary
Total Claims 19
30-Day Fills 31.0
Days Supply 930
CT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply940
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,670.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$87.94

State Avg Cost Per Claim

$307.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

Therapeutic Applications

Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

Ropinirole Hcl

Generic Formulation: Ropinirole HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 32
30-Day Fills 58.0
Days Supply 1,740
CT State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills43.4
Peer Average Days Supply1,264
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $604.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.88

State Avg Cost Per Claim

$23.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to treat Parkinson's disease. It can improve your ability to move and decrease shakiness (tremor), stiffness, slowed movement, and unsteadiness. It may also decrease the number of episodes of not being able to move (on-off syndrome). Ropinirole works by helping to restore the balance of a certain natural substance (dopamine) in the brain.

Rytary

Generic Formulation: Carbidopa/LevodopaSpecialty: Neurology
Provider Metrics Summary
Total Claims 33
30-Day Fills 37.0
Days Supply 1,008
CT State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills82.9
Peer Average Days Supply2,331
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,362.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$768.57

State Avg Cost Per Claim

$1,055.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Selegiline Hcl

Generic Formulation: Selegiline HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 40.0
Days Supply 1,200
CT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills46.5
Peer Average Days Supply1,343
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,011.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$215.11

State Avg Cost Per Claim

$129.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.

Therapeutic Applications

This medication is used to treat movement disorders caused by Parkinson's disease. It does not cure Parkinson's disease, but it may improve shakiness (tremor), muscle stiffness, loss of normal movement as your dose of other Parkinson's medication wears off (end-of-dose failure), and sudden switching between normal movement and stiffness (on-off problems). It may improve your range of motion and ability to walk, dress, and exercise. Selegiline is usually used in combination with other medicines (such as levodopa, carbidopa). Selegiline is an enzyme blocker (MAO inhibitor) that works by slowing the breakdown of certain natural substances in the brain (neurotransmitters such as dopamine, norepinephrine, and serotonin).

Trazodone Hcl

Generic Formulation: Trazodone HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 31
30-Day Fills 43.0
Days Supply 1,290
CT State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills109.1
Peer Average Days Supply3,071
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.5% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $211.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.83

State Avg Cost Per Claim

$13.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat depression. It may help to improve your mood, appetite, and energy level as well as decrease anxiety and insomnia related to depression. Trazodone works by helping to restore the balance of a certain natural chemical (serotonin) in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. AYSE SULE TINAZ M.D., PH.D. provides transparency into local medical care patterns within New Haven, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.